Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04534309
Other study ID # IRB00229163
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 22, 2020
Est. completion date June 30, 2023

Study information

Verified date October 2023
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Project


Description:

The objective of the ASPIRE Project is to design, implement, and evaluate a real-world, lifestyle-based, support for overweight or obese cancer survivors in both urban and rural areas of Maryland. The project will provide three options of support to encourage lifestyle change to achieve and maintain a healthy weight for cancer survivors: 1. Self-Directed Weight Loss: educational materials only; 2. App-Directed Weight Loss: educational materials, weight loss app with weekly e-mail support; and 3. Coach-Directed Weight Loss: educational materials, weight loss app, weekly e-mail support and one-to-one weekly telephonic coach support.


Recruitment information / eligibility

Status Completed
Enrollment 340
Est. completion date June 30, 2023
Est. primary completion date December 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - previously diagnosed with a malignant solid tumor, - completed all required surgical, and/or chemotherapy and/or radiation curative intent therapy at least three months prior to enrollment, - anticipated treatment-free life span of 12 months or longer. - chemoprophylaxis with tamoxifen or aromatase inhibitors for breast cancer in women will be permitted - anti- Luteinizing-hormone releasing therapy for prostate cancer in men will be permitted. - BMI = 25 kg/m2 (BMI = 23 kg/m2 for Asians) and weight = 400 lbs. - have an email address for regular personal use Additional criteria for participants in weight tracking (self-directed or app directed) - willingness to record/transmit quarterly weights for 12 months Additional criteria for App-Directed Program: - willingness to change diet and increase physical activity and track weight, diet and physical activity - have a smart phone for personal use - sufficient data plan/Internet to support daily use of weight loss app* Additional Criteria for Coach-Directed Weight Loss Program - willingness to lose weight by changing diet and physical activity habits - willingness to track weight, diet and physical activity - willingness to record/transmit quarterly weights for 12 months - smart phone for personal use - data plan/Internet to support daily use of weight loss app* - willingness to complete coaching calls (12 weekly calls and 3 monthly calls) - sufficient call plan to support coaching calls - a corresponding website could be used, then daily Internet access is required for person use. Exclusion Criteria: - received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed program date - women who are breastfeeding, pregnant, or planning pregnancy within the next year Additional exclusion criteria for participants in weight tracking and/or Coach-Directed Program - self-identification of uncontrolled concurrent medical condition likely to limit compliance with the program as determined by investigators. - current involvement in another organized weight loss program - current use of steroids or other medication known to affect body weight - bariatric surgery scheduled within the next 6 months, or - plan to move outside the continental US in the next 12 months

Study Design


Intervention

Behavioral:
Written Weight Loss Material
Participants will receive written weight loss material by email.
Weight Loss App
Participants will receive written weight loss material as well as instructions for using a free weight loss app on their phone or computer.
Behavioral Lifestyle Weight Loss Intervention (Coaching)
Participants will receive weekly coaching phone calls to encourage regular dietary, exercise, and self-monitoring practices which encourage gradual, healthy weight loss.

Locations

Country Name City State
United States Johns Hopkins ProHealth Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Maryland Cigarette Restitution Fund

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Program participation as assessed by participant enrollment Examine the enrollment in each program as a measure of program participation. End of enrollment, up to 2 years
Other Adoption of weight loss program activities as assessed by app use frequency Evaluate the "adoption" of the App-Directed Weight Loss Program and Coach-Directed Weight Loss Program by examining app-use frequency at six months. 6 months
Other Implementation of weight loss program as assessed by a participant survey Evaluate the implementation of the Coach-Directed Weight Loss Program through a participant survey. 6 months
Other Weight change at 12 months by program Evaluate the "maintenance" of the Self-Directed, App-Directed and Coach-Directed weight loss programs in a real world setting by examining weight change [in kilograms (kg)] at 12-months by program. Baseline and 12 months
Primary Weight change at 6 months in Coach-Directed Program Evaluate the "effectiveness" of the Coach-Directed weight loss programs in a real world setting by examining weight change [in kilograms (kg)] at 6-months. Baseline and 6 months
Secondary Weight change at 6 months in Self-Directed and App-Directed Weight Loss Programs Evaluate the "effectiveness" of the Self-Directed and App-Directed weight loss programs in a real world setting by examining weight change [in kilograms (kg)] at 6-months. Baseline and 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A